HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Lamivudine (3TC)

A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.

Also Known As:

3TC; Epivir; 2',3' Dideoxy 3' thiacytidine; BCH-189; GR-109714X; GR109714X; Lamivudine, (2S-cis)-Isomer; BCH 189; BCH189; 2',3'-Dideoxy-3'-thiacytidine; 2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-

Networked: 3211 relevant articles (574 outcomes, 642 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Kumada, Hiromitsu: 44 articles (06/2014 - 01/2002)
2.	Suzuki, Fumitaka: 41 articles (06/2014 - 01/2002)
3.	Lai, Ching-Lung: 36 articles (06/2014 - 07/2002)
4.	Akuta, Norio: 34 articles (06/2014 - 01/2002)
5.	Suzuki, Yoshiyuki: 33 articles (06/2014 - 01/2002)
6.	Kobayashi, Masahiro: 33 articles (06/2014 - 01/2002)
7.	Ikeda, Kenji: 33 articles (06/2014 - 01/2002)
8.	Arase, Yasuji: 32 articles (06/2014 - 01/2002)
9.	Liaw, Yun-Fan: 29 articles (05/2015 - 04/2002)
10.	Hosaka, Tetsuya: 29 articles (06/2014 - 01/2003)

Related Diseases

1.	Chronic Hepatitis B 01/01/2002 - "However, durable posttreatment remission of chronic hepatitis B has not been shown to occur in a significant number of lamivudine-treated patients. " 07/01/2001 - "A long-term follow-up study was carried out to evaluate the tolerability and efficacy of long-term therapy (1 to 3 years) with high doses (150 or 300 mg daily) of lamivudine for chronic hepatitis B. " 04/01/2009 - "Anti-HBV therapeutic trials in Asia have shown that AE of chronic hepatitis B (CH-B) may result in increased sustained remission (SR) rate with lamivudine monotherapy. " 06/01/2007 - "The aim of this study was to compare the efficacy of lamivudine therapy between chronic hepatitis B (CHB) patients, whose ALT levels less than 2 times the upper limit of normal (ULN) and patients whose ALT levels are more than 2 times ULN. " 04/01/2005 - "The major aim of our study was the assessment of the efficacy of lamivudine therapy in children with chronic hepatitis B (CHB). "
2.	Hepatitis B 08/01/2000 - "Lamivudine is highly effective in suppressing hepatitis B viral replication and hepatic necroinflammatory activity. " 02/01/2014 - "Considering the limited potency and high resistance rates to lamivudine therapy, our study emphasizes the use of more potent drugs in the management of chronic hepatitis B in the Indian subcontinent." 12/01/2011 - "This analysis suggests that supplemental use of lamivudine in mothers with high hepatitis B viraemia is effective in reducing vertical transmission and may be cost effective, from a Taiwanese societal perspective, compared with the routine active-passive immunization without lamivudine." 03/01/2009 - "Hepatitis B was treated successfully with lamivudine. " 03/01/2009 - "The obtained results suggest significant efficacy of lamivudine in patients with subacute hepatitis B. "
3.	Infection 01/01/2006 - "However, a combination of lamivudine and siRNA-M184V was very effective in inhibiting replication of both wild-type and variant M184V viruses in mixed infection experiments. " 02/01/1999 - "Lamivudine has proven to be very effective in the treatment of both de novo and recurrent HBV infection after OLTx; however, resistance can develop. " 02/01/2001 - "Recently, Lamivudine has been licensed for use against HBV infection with good results. " 01/01/2004 - "Lamivudine is effective in the treatment of HBV infection in the dialysis setting. " 03/01/2002 - "In vitro and in vivo prophylactic and therapeutic efficacy of AZT/3TC treatment was evaluated against feline immunodeficiency virus (FIV) infection. "
4.	Fibrosis (Cirrhosis) 12/01/2002 - "Although several clinical trials have suggested that lamivudine treatment can be very effective in patients with decompensated HBV-associated cirrhosis, its role and clinical efficacy are still uncertain because of the study designs. " 04/01/2007 - "It has been statistically proven that the efficacy of lamivudine therapy correlates with degree of fibrosis and higher histological activity index values. " 09/01/2003 - "Significant improvement in liver histology, both necroinflammation and fibrosis, can be obtained in the majority of patients treated with lamivudine for one year." 01/01/2003 - "One-year of Lamivudine treatment significantly improved necroinflammation and reduced the progression of fibrosis and the histologic activity index. " 07/01/2000 - "One-year lamivudine therapy significantly suppressed hepatitis B virus (HBV) replication, improved hepatic necroinflammatory activity, and prevented progression of fibrosis. "
5.	Hepatitis 03/01/2009 - "Lamivudine has been established as a safe and effective antiviral agent for the treatment of chronic HBV hepatitis. " 02/01/2006 - "The aim of this study was to evaluate the efficacy of preemptive lamivudine therapy in reducing hepatitis due to HBV reactivation in patients with HCC undergoing transarterial chemo-lipiodolization (TACL) and to seek predictors of this event. " 01/01/2004 - "Among patients with hepatitis reactivation, two were treated with lamivudine resulting in dramatic improvement and clinical remission of the disease. " 09/01/2015 - "The aim of the present study was to determine the prevalence of precore and lamivudine drug resistance mutations in lamivudine treated patients with chronic B hepatitis. " 07/01/2014 - "Lamivudine-withdrawal hepatitis was not detected; however, one case of breakthrough HBV reactivation during lamivudine treatment was observed in this study. "

Related Drugs and Biologics

1.	Hepatitis B e Antigens
2.	adefovir
3.	entecavir
4.	adefovir dipivoxil (Hepsera)
5.	lipoarabinomannan (LAM)
6.	Antigens
7.	Interferons
8.	DNA (Deoxyribonucleic Acid)
9.	Lamivudine (3TC)
10.	Interferon-alpha (Interferon Alfa)

Related Therapies and Procedures

1.	Liver Transplantation
2.	Drug Therapy (Chemotherapy)
3.	Transplantation (Transplant Recipients)
4.	Transplants (Transplant)
5.	Homologous Transplantation (Allograft)